Arcutis Biotherapeutics I...

NASDAQ: ARQT · Real-Time Price · USD
13.98
0.32 (2.34%)
At close: May 23, 2025, 3:59 PM
14.27
2.04%
After-hours: May 23, 2025, 06:46 PM EDT

Company Description

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.

Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.

The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata.

The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019.

Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc. logo
Country United States
IPO Date Jan 31, 2020
Industry Biotechnology
Sector Healthcare
Employees 342
CEO Todd Franklin Watanabe M.A.

Contact Details

Address:
3027 Townsgate Road
Westlake Village, California
United States
Website https://www.arcutis.com

Stock Details

Ticker Symbol ARQT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001787306
CUSIP Number 03969K108
ISIN Number US03969K1088
Employer ID 81-2974255
SIC Code 2834

Key Executives

Name Position
Todd Franklin Watanabe M.A. President, Chief Executive Officer & Director
Latha Vairavan Chief Financial Officer
Aleen Hosdaghian Vice President of Marketing
Amanda Sheldon Head of Corporate Communications
Courtney Barton Vice President and Chief Compliance Officer & Privacy Officer
Dr. Bhaskar Chaudhuri Ph.D. Co-Founder & Independent Director
Dr. Patrick E. Burnett M.D., Ph.D. Executive Vice President & Chief Medical Officer
Kent Taylor Senior Vice President of Sales
Masaru Matsuda Esq., J.D. Senior Vice President, General Counsel & Corporate Secretary
Rajvir Madan Chief Digital & Technology Officer

Latest SEC Filings

Date Type Title
May 20, 2025 4 Filing
May 19, 2025 4 Filing
May 15, 2025 SCHEDULE 13G/A [Amend] Filing
May 15, 2025 4 Filing
May 15, 2025 SCHEDULE 13G/A [Amend] Filing
May 13, 2025 4 Filing
May 09, 2025 4 Filing
May 08, 2025 SCHEDULE 13G/A [Amend] Filing
May 07, 2025 4 Filing
May 07, 2025 3 Filing